GlassScriptPhysician profile
Paul Rodenhouse
NPI 1508285388
$15,361.69
in general payments reported to CMS, 2019-2025
10 companies · $559 in 2025
The $559 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,472 · 2020: $3,749 · 2021: $7,212 · 2022: $736 · 2023: $259 · 2024: $376 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046 · Travel and Lodging: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.69 |
| Travel and Lodging | $147.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $6,795.05 | 2020-2021 | |
| Pinnacle, INC | $2,471.50 | 2019 | |
| Stryker Corporation | $2,347.91 | 2021-2025 | Blueprint Patient Specific Instrumentation, Mako, Gamma |
| Crossroads Orthopedics, LLC | $2,108.26 | 2021-2023 | |
| Encore Medical, LP | $807.29 | 2020-2024 | Djo Surgical |
| Zimmer Biomet Holdings, INC. | $565.52 | 2024-2025 | Persona, Synovasure Alpha Defensin, Biocue |
| Depuy Synthes Sales INC. | $143.35 | 2020-2025 | Tfn-Advance, Na |
| Smith+Nephew, INC. | $90.78 | 2021-2025 | Journey II |
| Anika Therapeutics, INC. | $25.91 | 2021 | |
| Orthofix Medical, INC. | $6.12 | 2025 | Physio-Stim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rodenhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.